On June 29, Liquidia Technologies fell 5.37% in regular trading, trading at $73.09/share, with turnover of approximately $31.95 million.

On the news front, BofA Securities downgraded Liquidia from Buy to Neutral, setting a price target of $79. The stock had risen in pre-market trading on strong YUTREPIA commercialization momentum and upcoming poster presentations at the PHA International PH Conference, but the downgrade triggered profit-taking pressure during regular hours.

Fundamentally, the company reported robust Q1 results with EPS of $0.52, beating the consensus estimate of $0.41 by approximately 27%. YUTREPIA net product sales reached roughly $130 million with over 4,500 unique patient prescriptions, marking a swing to profitability from a loss of $0.45 per share in the year-ago quarter. Despite the strong operational performance, the downgrade suggests current valuations may have fully priced in near-term catalysts, limiting further upside potential.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)